Obiltoxaximab
Anthim, Obiltoxaximab SFL (obiltoxaximab) is an antibody pharmaceutical. Obiltoxaximab was first approved as Anthim on 2016-03-18. It is used to treat anthrax, crohn disease, and graft vs host disease in the USA. It has been approved in Europe to treat anthrax.
| Trade Name | Obiltoxaximab SFL |
|---|---|
| Common Name | Obiltoxaximab |
| Indication | anthrax, crohn disease, graft vs host disease |
| Drug Class | Monoclonal antibodies: toxin as a target |
